

Full Portfolio Holdings* as of March 31, 2024

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			7,517,156	7,517,156	0.66%
COMMON STOCKS					
Eli Lilly & Co.			159,790	124,310,228	10.98%
UnitedHealth Group, Inc.			151,993	75,190,937	6.64%
Merck & Co., Inc.			551,946	72,829,275	6.43%
Danaher Corp.			170,520	42,582,254	3.76%
Stryker Corp.			89,712	32,105,233	2.84%
Boston Scientific Corp.			467,927	32,048,320	2.83%
HCA Healthcare, Inc.			86,077	28,709,262	2.54%
Thermo Fisher Scientific, Inc.			48,954	28,452,554	2.51%
AbbVie, Inc.			150,113	27,335,577	2.41%
Vertex Pharmaceuticals, Inc.			60,927	25,468,095	2.25%
Centene Corp.			306,918	24,086,925	2.13%
Cencora, Inc.			97,722	23,745,469	2.10%
Abbott Laboratories			199,788	22,707,904	2.01%
Edwards Lifesciences Corp.			227,872	21,775,448	1.92%
Zoetis, Inc.			126,495	21,404,219	1.89%
AstraZeneca PLC			289,990	19,646,823	1.74%
Dexcom, Inc.			140,254	19,453,230	1.72%
Regeneron Pharmaceuticals, Inc.			19,536	18,803,205	1.66%
Molina Healthcare, Inc.			43,420	17,838,239	1.58%
Agilent Technologies, Inc.			119,044	17,322,092	1.53%
Humana, Inc.			47,786	16,568,362	1.46%
Acadia Healthcare Co., Inc.			202,293	16,025,651	1.42%
Daiichi Sankyo Co. Ltd.			489,225	15,566,588	1.38%
Shockwave Medical, Inc.			47,336	15,414,022	1.36%
ICON PLC			45,738	15,365,681	1.36%
Laboratory Corp. of America Holdings			48,217	10,533,486	0.93%
Illumina, Inc.			69,589	9,555,961	0.84%
Hologic, Inc.			114,314	8,911,919	0.79%
Encompass Health Corp.			103,769	8,569,244	0.76%
Pfizer, Inc.			304,036	8,436,999	0.75%
Argenx SE			21,250	8,366,550	0.74%
Waters Corp.			23,657	8,143,449	0.72%
GSK PLC			377,018	8,094,718	0.72%
Chugai Pharmaceutical Co. Ltd.			209,500	8,006,123	0.71%
Insulet Corp.			45,984	7,881,658	0.70%
Option Care Health, Inc.			233,731	7,839,338	0.69%
Novartis AG			77,634	7,519,504	0.66%
Galderma Group AG			101,983	7,163,745	0.63%
UCB SA			57,033	7,040,544	0.62%
Eisai Co. Ltd.			170,195	7,010,123	0.62%

Full Portfolio Holdings* as of March 31, 2024

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Repligen Corp.			36,452	6,704,252	0.59%
Biogen, Inc.			30,533	6,583,831	0.58%
Evolent Health, Inc.			198,617	6,512,651	0.58%
Addus HomeCare Corp.			59,655	6,164,748	0.54%
Otsuka Holdings Co. Ltd.			143,500	5,960,742	0.53%
United Therapeutics Corp.			25,844	5,936,884	0.52%
Elanco Animal Health, Inc.			363,266	5,913,970	0.52%
Qiagen NV			131,338	5,646,221	0.50%
Teleflex, Inc.			23,601	5,337,838	0.47%
Surgery Partners, Inc.			175,740	5,242,324	0.46%
Alnylam Pharmaceuticals, Inc.			34,869	5,211,172	0.46%
Exact Sciences Corp.			73,707	5,090,205	0.45%
Ascendis Pharma AS			33,514	5,066,311	0.45%
agilon health, Inc.			823,195	5,021,490	0.44%
Celldex Therapeutics, Inc.			119,363	5,009,665	0.44%
REVOLUTION Medicines, Inc.			153,298	4,940,795	0.44%
Apellis Pharmaceuticals, Inc.			82,257	4,835,066	0.43%
Immunocore Holdings PLC			72,998	4,744,870	0.42%
Crinetics Pharmaceuticals, Inc.			99,828	4,672,949	0.41%
Cytokinetics, Inc.			65,537	4,594,799	0.41%
Sarepta Therapeutics, Inc.			33,847	4,381,833	0.39%
Tecan Group AG			10,274	4,256,823	0.38%
Amgen, Inc.			14,822	4,214,191	0.37%
Privia Health Group, Inc.			214,428	4,200,645	0.37%
Structure Therapeutics, Inc.			95,845	4,107,917	0.36%
DiaSorin SpA			42,308	4,082,922	0.36%
Merus NV			86,359	3,888,746	0.34%
Alkermes PLC			140,734	3,809,669	0.34%
Vaxcyte, Inc.			55,654	3,801,725	0.34%
Syndax Pharmaceuticals, Inc.			154,467	3,676,315	0.32%
Rocket Pharmaceuticals, Inc.			132,592	3,572,028	0.32%
Bio-Techne Corp.			50,651	3,565,324	0.31%
Genmab AS			11,857	3,555,067	0.31%
Inari Medical, Inc.			73,040	3,504,459	0.31%
Ultragenyx Pharmaceutical, Inc.			72,881	3,402,814	0.30%
Moderna, Inc.			30,781	3,280,023	0.29%
Veracyte, Inc.			147,100	3,259,736	0.29%
Blueprint Medicines Corp.			33,901	3,215,849	0.28%
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.			161,600	3,207,894	0.28%
Xenon Pharmaceuticals, Inc.			73,821	3,177,994	0.28%
Gilead Sciences, Inc.			42,173	3,089,172	0.27%
Verona Pharma PLC			182,431	2,935,315	0.26%
Bridgebio Pharma, Inc.			86,489	2,674,240	0.24%
Immatics NV			239,842	2,520,739	0.22%
Soleno Therapeutics, Inc.			58,083	2,485,952	0.22%

Full Portfolio Holdings* as of March 31, 2024

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Longboard Pharmaceuticals, Inc.			113,466	2,450,866	0.22%
Autolus Therapeutics PLC			377,682	2,409,611	0.21%
Genus PLC			106,831	2,376,296	0.21%
Legend Biotech Corp.			41,605	2,333,624	0.21%
Akero Therapeutics, Inc.			92,059	2,325,410	0.21%
PTC Therapeutics, Inc.			67,671	1,968,549	0.17%
Inspire Medical Systems, Inc.			8,877	1,906,691	0.17%
Zai Lab Ltd.			92,448	1,481,017	0.13%
Morphic Holding, Inc.			37,553	1,321,866	0.12%
Prothena Corp. PLC			45,519	1,127,506	0.10%
Smith & Nephew PLC			56,056	701,764	0.06%
Contra Abiomed, Inc.			7,416	7,564	0.00%
FOREIGN CURRENCY					
BRAZILIAN REAL			1,906,284	380,086	0.03%
JAPANESE YEN			17,976,601	118,751	0.01%
POUND STERLING			11,700	14,768	0.00%
EURO CURRENCY			117	126	0.00%
DANISH KRONE			447	65	0.00%
SWISS FRANC			12	13	0.00%
HONG KONG DOLLAR			37	5	0.00%
SHORT-TERM INVESTMENTS					
Fixed Income Clearing Corp.		4/1/2024	1,929,110	1,929,110	0.17%
DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)					
SWISS FRANC		4/2/2024	587,082	2,688	0.00%
JAPANESE YEN		4/1/2024	(17,976,600)	5	0.00%
POUND STERLING		4/2/2024	(11,700)	3	0.00%
BRAZILIAN REAL		4/2/2024	(9,837,383)	(39)	0.00%
SWISS FRANC		4/3/2024	235,125	(49)	0.00%
TOTAL INVESTMENTS				1,125,260,582	99.40%
OTHER ASSETS LESS LIABILITIES				6,801,855	0.60%
TOTAL NET ASSETS				1,132,062,437	100.00%

Full Portfolio Holdings* as of March 31, 2024

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22